This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. The impact could be huge for the biopharma industry. Novo Nordisk Pharmatech is excited to support the new modalities at the very forefront of the biopharma industry.
When Marc’s doctors discovered he had a rare liver condition, it almost felt like a relief. That’s what doctors are taught, so we can’t be surprised that many patients with a “zebra” condition get the “horse” treatment. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.
The share using physician-only social networks on a monthly basis has increased to 82%, from 58% in 2019, and 37% read pharma email newsletters weekly, versus 30% pre-pandemic (some specialists are more digitally-mature than others – particularly hematology-oncologists, endocrinologists and gastroenterologists).Meanwhile,
Cure” put me on a path to work across a network of incredibly smart, passionate, and well-meaning stakeholders to connect dots, create forums for sharing ideas, drive patient-centered approaches, and eliminate lost-in-translation moments. However, I don’t believe there is, or should be, only one way of gathering patient feedback.
Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. .
Accelerated timelines are possible with parallel process development and tech transfer, leveraging a CDMOs platform process knowledge, network capabilities and expertise. She completed post-doctoral training at Johnson & Johnson and the University of California San Diego in pharmacology and bioengineering.
Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate PhD from the Institute of Cancer Research in London.
Our ambition is to build a modern, industry-leading manufacturing network, by bringing together talented people and cutting-edge processes, technologies and data to reliably deliver high quality, affordable and sustainable medicines and vaccines to patients. Brendan O’Callaghan leads an international network of manufacturing sites.
For example, a biopharma may want to track the improvement in patient adherence to a therapy pre- and post-launch of a PSP across regions to gauge its impact. A system that connects patients with their entire care team—doctors, specialists, therapists—ensures everyone is on the same page. Our programs can be the map that guides them.
A key catalyst in that translational process is the venture capital community that not only provides financial resources, but also network and management support to advance the development of new medicines and treatments. As you know, you couldn’t go and see your doctor in the clinic.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content